Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of RAVICTI in pediatric subjects under two years of age with urea cycle disorders
2016-003460-38Phase 4
- Sponsor
- Horizon Therapeutics
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sodium phenylbutyrate in urea cycle disorder (UCD), sponsored by Horizon Therapeutics. Primary endpoint: Successful transition to RAVICTI with controlled ammonia.
02
Drugs
sodium phenylbutyrate
03
Conditions
urea cycle disorder (UCD)
Beyond the preview
Go deeper on 2016-003460-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003460-38.